Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14989523 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL9503018 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| Octane SCHEMBL16440085 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL8345503 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL440982 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1066766 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2016841 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1517931 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL571427 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL136430 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150110713-A1 | METHOD AND COMPOSITION FOR TREATING CANCER | MANGANARO ANTHONY (US) | 2015-04-23 | — | — | US | claimed |
| US-20120164065-A1 | METHOD AND COMPOSITION FOR TREATING CANCER | MANGANARO ANTHONY (US) | 2012-06-28 | — | — | US | claimed |
| WO-2008112565-A9 | METHOD AND COMPOSITION FOR TREATING CANCER | ROCKWELL KAREN (US) | 2009-02-19 | — | — | WO | claimed |
| US-20080279764-A1 | METHOD AND COMPOSITION FOR TREATING CANCER | Manganaro, Anthony (US) | 2008-11-13 | — | — | US | claimed |
| WO-2008112565-A2 | METHOD AND COMPOSITION FOR TREATING CANCER | MANGANARO ANTHONY (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2005110363-A2 | SYSTEMS AND METHODS FOR PREPARATION OF PHARMACEUTICAL DOSAGE USING COMPOSITIONS CONTAINING AQUEOUS VESICLES | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050232973-A1 | Systems and methods for preparation of pharmaceutical dosage using compositions containing aqueous vesicles | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2005-10-20 | — | — | US | claimed |
| US-20040101932-A1 | Compositions and methods for targeted enzymatic release of cell regulatory compounds | MARKER GENE TECHNOLOGIES, INC. | 2004-05-27 | — | — | US | claimed |
| EP-0871758-B1 | LIPOSOMAL TRANSFECTION METHOD | KINNUNEN PAAVO KAI JOHANNES (FI) | 2004-03-31 | — | — | EP | claimed |
| EP-1200131-A2 | COMPOSITIONS AND METHODS FOR TARGETED ENZYMATIC RELEASE OF CELL REGULATORY COMPOUNDS | Marker Gene Technologies, Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| WO-2001002020-A2 | COMPOSITIONS AND METHODS FOR TARGETED ENZYMATIC RELEASE OF CELL REGULATORY COMPOUNDS | MARKER GENE TECHNOLOGIES, INC. (US) | 2001-01-11 | — | — | WO | claimed |
| US-6074667-A | Liposomal transfection method | KINNUNEN PAAVO (FI) | 2000-06-13 | — | — | US | claimed |
| EP-0871758-A1 | LIPOSOMAL TRANSFECTION METHOD | KINNUNEN, Paavo Kai Johannes (FI) | 1998-10-21 | — | — | EP | claimed |
| WO-1997019184-A1 | LIPOSOMAL TRANSFECTION METHOD | KINNUNEN PAAVO (FI) | 1997-05-29 | — | — | WO | claimed |
| EP-4370162-A1 | CATIONIC CALIBRATED-SIZE GAS-FILLED MICROVESICLES | Bracco Suisse SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-20240082463-A1 | COATED MEDICAL PRODUCT | HEMOTEQ AG (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20230414839-A1 | COATED MEDICAL PRODUCT | HEMOTEQ AG (DE) | 2023-12-28 | — | — | US | disclosed |
| US-4816450-A | ANTIINFLAMMATORY AGENTS, AMINE COMPOUNDS | DUKE UNIVERSITY (US) | 1989-03-28 | — | — | US | disclosed |
| EP-0282564-A1 | INHIBITION OF PROTEIN KINASE C BY LONG-CHAIN BASES | DUKE UNIVERSITY (US) | 1988-09-21 | — | — | EP | disclosed |
| WO-1988001869-A1 | INHIBITION OF PROTEIN KINASE C BY LONG-CHAIN BASES | DUKE UNIVERSITY (US) | 1988-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414839-A1 | COATED MEDICAL PRODUCT | PLOD3, MBOAT1, PLA2G2D | FAAH 153/4885CES1 2172/4885CES2 2134/4885 |
| US-20040101932-A1 | Compositions and methods for targeted enzymatic release of cell regulatory compounds | GUSB, PREP, PEPD | FAAH 696/4885CES1 150/4885CES2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.